文献速递乳腺癌放疗

接受放射治疗的乳腺癌患者中新诊断的精神健康障碍

Newly Diagnosed Mental Health Disorders in Patients With Breast Cancer Receiving Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-04

本研究利用单中心前瞻性维护数据库,分析2012至2017年接受放射治疗的967例乳腺癌患者,在乳腺癌诊断后3年内新发精神健康障碍(MHD)的情况。318例(33%)出现新发MHD,以焦虑和抑郁为主,中位诊断时间为30个月;多因素分析显示化疗、离异状态、全乳加区域淋巴结照射及乳房切除术后放射治疗与MHD发生相关。

要点

  • 967例接受放射治疗的乳腺癌患者中318例(33%)新发精神健康障碍,以焦虑(45.1%)和抑郁(20.1%)为主。
  • 多因素分析中化疗(HR 1.70,P=.014)与离异状态(HR 2.04,P=.009)与新发MHD显著相关。
  • 全乳加区域淋巴结照射(HR 2.31,P=.015)和乳房切除术后放射治疗(HR 1.88,P=.024)均为MHD的强预测因素。

核心结论

  • 在该队列中,1/3的局限性乳腺癌患者出现新发精神健康障碍,主要与焦虑和抑郁相关。
  • 离异患者、接受化疗的患者以及接受乳房切除术后放射治疗或全乳加区域淋巴结照射的患者MHD风险更高。
  • 作者认为这些发现凸显了未来研究和针对性干预以支持这一脆弱人群的重要性。

研究设计与样本

  • 单中心、前瞻性维护数据库分析,纳入2012至2017年接受放射治疗的乳腺癌患者967例。
  • 将患者与乳腺癌诊断后3年内新获得的国际疾病分类第十版(ICD-10)精神健康障碍编码(F01-F99)进行交叉比对。
  • 研究包含基线美国国家综合癌症网络(NCCN)痛苦量表评分和区域剥夺指数(ADI)。
  • 采用单因素和多因素Cox回归分析评估影响新发MHD的因素。

主要发现

  • 967例患者中318例(33%)在乳腺癌诊断后出现MHD,主要为焦虑(45.1%)和抑郁(20.1%)相关,中位(IQR)诊断时间为30(24-33)个月。
  • 单因素分析显示淋巴结阳性疾病、接受化疗、接受乳房切除术、高合并症指数、离异状态、退休状态及ADI第四四分位数均为显著预测因素。
  • 多因素分析中仅接受化疗(HR 1.70;P=.014)和离异状态(HR 2.04;P=.009)仍显著。
  • ADI第四四分位数、退休状态和高合并症指数呈接近显著的trend(HR 1.78,P=.065;HR 1.46,P=.094;HR 1.41,P=.059)。
  • 多因素分析显示全乳加区域淋巴结照射(HR 2.31,P=.015)和乳房切除术后放射治疗(HR 1.88,P=.024)均为MHD发生的强预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with a mental health disorder (MHD) have higher age-adjusted mortality compared with the general population. Few reports investigate factors contributing to MHD among patients with breast cancer receiving radiation therapy. We report the incidence of acquired MHD after the diagnosis of breast cancer and treatment with radiation therapy. METHODS AND MATERIALS: Using a single institution, prospectively maintained database, we analyzed patients with breast cancer treated with radiation therapy between 2012 and 2017. We cross-referenced these patients with newly acquired International Classification of Diseases, Tenth Revision (ICD-10) MHD codes (F01-F99) within 3 years postbreast cancer diagnosis. The study included baseline National Comprehensive Cancer Network® (NCCN) distress tool scores and area deprivation index (ADI). Univariate and multivariable (MVA) Cox regression analyses were conducted to evaluate factors affecting new MHD onset. RESULTS: Of the 967 included patients, 318 (33%) developed an MHD after their breast cancer diagnosis, which was predominately anxiety (45.1%) and depression (20.1%) related, with a median (IQR) time to diagnosis of 30 (24-33) months. Univariate analysis showed lymph node-positive disease, receipt of chemotherapy, receipt of a mastectomy, high comorbidity index, divorced status, retired status, and fourth-quartile ADI as significant predictors. On MVA, only receipt of chemotherapy (hazard ratio [HR], 1.70; P = .014) and divorced status (HR, 2.04; P = .009) remained significant. Fourth-quartile ADI, retired status, and high comorbidity index showed trends toward significance (HR, 1.78, P = .065; HR, 1.46, P = .094; HR, 1.41, P = .059, respectively). On MVA examining the effects of the radiation therapy type on MHD, whole breast with regional nodal irradiation (HR, 2.31, P = .015) and postmastectomy radiation therapy (HR, 1.88, P = .024) were both strong predictors of MHD development. Additionally, an NCCN distress tool score of >3 was also predictive of MHD onset. CONCLUSIONS: In this cohort, 1 in 3 patients with localized breast cancer developed a new MHD, predominantly related to anxiety and depression. MHD risk was higher among divorced patients, those receiving chemotherapy, and patients receiving postmastectomy radiation therapy or whole breast with regional nodal irradiation. These findings highlight the importance of future studies and targeted interventions to support this vulnerable population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Loving BA, Almahariq MF, Sivapalan S, et al. Newly Diagnosed Mental Health Disorders in Patients With Breast Cancer Receiving Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38582232. doi:10.1016/j.ijrobp.2024.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。